Introduction Dupilumab has been approved as add-on therapy for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) since 2019. The aim of this study is to investigate compliance, associated comorbidities, symptom development and side effects after several years of clinical use.
No takes yet. Share an insight, caveat, or question.
Sakmen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: